



(12) Translation of
European patent specification

(11) NO/EP 3653221 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 38/00 (2006.01)

C07K 14/00 (2006.01)

C12N 15/113 (2010.01)

A61P 35/00 (2006.01)

C07K 16/28 (2006.01)

Norwegian Industrial Property Office

- (45) Translation Published 2022.12.12
- (80) Date of The European Patent Office Publication of the Granted Patent 2022.08.03
- (86) European Application Nr. 19214231.3
- (86) European Filing Date 2016.02.19
- (87) The European Application's Publication Date 2020.05.20
- (30) Priority 2015.02.19, US, 201562118208 P
2015.03.31, US, 201562141120 P
2015.10.01, US, 201562235823 P
- (84) Designated Contracting States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
- (62) Divided application EP3258951, 2016.02.19
- (73) Proprietor Compugen Ltd., 26 Harokmim Street, 5885849 Holon, Israel
- (72) Inventor WHITE, Mark, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
KUMAR, Sandeep, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
CHAN, Christopher, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
LIANG, Spencer, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
STAPELTON, Lance, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
DRAKE, Andrew W., c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
GOZLAN, Yosi, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
VAKNIN, Ilan, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
SAMEAH-GREENWALD, Shirley, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
DASSA, Liat, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
TIRAN, Zohar, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
COJOCARU, Gad S., c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
PRESTA, Leonard, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
THEOLIS, Richard, c/o Compugen Ltd. 26 Harokmim Street, 5885849 Holon, Israel
- (74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge
-

(54) Title **ANTI-PVRIG ANTIBODIES AND METHODS OF USE**

(56) References
Cited: WO-A1-2012/178128, WO-A1-2017/041004, EP-A1- 2 067 791, WO-A2-2004/058805
WO-A1-2017/021526,

IBA Y ET AL: "CHANGES IN THE SPECIFICITY OF ANTIBODIES AGAINST STEROID ANTIGENS BY INTRODUCTION OF MUTATIONS INTO COMPLEMENTARITY-DETERMINING REGIONS OF THE VH DOMAIN", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 5, 1 January 1998 (1998-01-01), pages 361-370, XP002953909, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.5.361

WINKLER K ET AL: "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505-4514, XP002579393, ISSN: 0022-1767

XIN YU ET AL: "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells", NATURE IMMUNOLOGY, vol. 10, no. 1, 1 January 2009 (2009-01-01), pages 48-57, XP055273979, GB ISSN: 1529-2908, DOI: 10.1038/ni.1674

RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979-1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979

N. STANIETSKY ET AL: "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858-17863, XP055215810, ISSN: 0027-8424, DOI: 10.1073/pnas.0903474106

ZHU YUWEN ET AL: "Identification of CD112R as a novel checkpoint for human T cells", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167-176, XP009190107, ISSN: 1540-9538

GALIT ROTMAN ET AL: "Identification of novel immune checkpoints as targets for cancer immunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), page P135, XP021167082, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P135

Gene Id: "PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083
Specification PVRIG antibody -middle region -Product Information Application WB Primary
Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted
Human Host Rabbit Clonality Polyclonal Calculated MW 34k", Physiol. Genomics, 1 January
2006 (2006-01-01), pages 201-218, XP055273924, Retrieved from the Internet:
URL:<http://www.funakoshi.co.jp/data/datash eet/ABG/AI13083.pdf>

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1.** Et anti-PVRIG-antistoff for bruk i behandling av kreft,

hvori antistoffet aktiverer T-celler og/eller NK-celler, antistoffet som spesifikt binder seg til humant PVRIG og konkurrerer med et antistoff som omfatter v_hCDR1 som angitt i SEKV ID NR:885, v_hCDR2 som angitt i SEKV ID NR:886, v_hCDR3 som angitt i SEKV ID NR:887, v_iCDR1 som angitt i SEKV ID NR:889, v_iCOR2 som angitt i SEKV ID NR:890 og v_iCDR3 som angitt i SEKV ID NR:891 for spesifikt å bindes til PVRIG-molekylet.

2. Anti-PVRIG-antistoff for bruk i behandlingen av kreft ifølge krav 1, hvori anti-PVRIG-antistoffet brukes i kombinasjon med antagonistiske antistoffer som målretter ytterligere immunkontrollpunkter.

3. Anti-PVRIG-antistoff for bruk i behandling av kreft ifølge krav 2, hvori de antagonistiske antistoffene som retter seg mot ytterligere immunkontrollpunkter inkluderer anti-CTLA-4-antistoffer, anti-PD-1-antistoffer, anti-PD-L1-antistoffer, anti-LAG-3 antistoffer, anti-TIM-3 antistoffer, anti-BTLA antistoffer, anti-B7-H4 antistoffer, anti-B7-H3 antistoffer og anti-VISTA antistoffer.

4. Anti-PVRIG-antistoff for bruk i behandlingen av kreft ifølge krav 3, hvori anti-CTLA4-antistoffer inkluderer ipilimumab og tremelimumab.

5. Anti-PVRIG-antistoff for bruk i behandlingen av kreft ifølge krav 3, hvori anti-PD-1-antistoffer inkluderer nivolumab, pidilizumab og pembrolizumab.

6. Anti-PVRIG-antistoff for bruk i behandlingen av kreft ifølge krav 3, hvori anti-PDL-1-antistoffer inkluderer atezolizumab og durvalumab.

7. Anti-PVRIG-antistoff for bruk i behandlingen av kreft ifølge krav 1, hvori anti-PVRIG-antistoffet brukes i kombinasjon med et anti-TIGIT-antistoff.